Artificial Intelligence in the Early Detection of Cardiovascular Disease in the United States

Cardiovascular disease (CVD) remains the leading cause of mortality in the United States, placing an immense strain on the national healthcare infrastructure and the economy. While clinical interventions have advanced significantly over the last three decades, the shift from reactive treatment to proactive prevention is hindered by the limitations of traditional diagnostic methods. Standard risk assessment tools, such as the Framingham Risk Score, often rely on static variables that fail to capture the dynamic, non-linear physiological changes preceding a major cardiac event. This diagnostic gap has paved the way for the integration of Artificial Intelligence (AI) into clinical workflows. By processing vast datasets—ranging from electronic health records to high-resolution imaging—AI-driven models offer a level of predictive precision previously unattainable. (Nguy, 2026) observes that the impact of AI extends across the entire continuum of cardiovascular care, fundamentally altering how clinicians identify, diagnose, and manage heart disease. Despite the technical prowess of these algorithms, their implementation within the United States clinical environment faces significant hurdles. The "black box" nature of deep learning models creates a transparency deficit, making it difficult for practitioners to trust algorithmic outputs in high-stakes medical decisions. suggests that the potential for AI-driven diagnosis and treatment is vast, particularly when considering the intersection of interoception and cardiac health, yet the path to clinical adoption is obstructed by concerns over data integrity and interpretability. Furthermore, the reliance on historical medical data introduces the risk of institutionalized bias. identifies critical biases in AI-driven CVD detection, noting that if training data lacks diversity, the resulting models may systematically underperform for marginalized groups, thereby widening existing health disparities rather than closing them. The problem this research addresses is the tension between the high diagnostic efficacy of AI models and the lack of a standardized, ethical governance framework to ensure their equitable deployment. Current regulatory structures in the United States, primarily overseen by the Food and Drug Administration (FDA), are struggling to keep pace with the iterative nature of machine learning. Static regulatory approvals are often ill-suited for algorithms that evolve as they ingest more data. This regulatory lag, combined with the ethical complexities of algorithmic bias, creates a precarious environment for both patients and providers. argues that ethical governance from a health policy perspective is no longer optional but a prerequisite for the sustainable management of cardiovascular disease through AI. Addressing these challenges requires a focused investigation into specific patient populations and diagnostic categories. For instance, the burden of cardiovascular disease is not distributed equally across genders. posits that leveraging AI for imaging can specifically improve outcomes for women, who have historically been underrepresented in cardiac research and clinical trials. Similarly, the application of AI in specialized screenings, such as preconception cardiomyopathy detection, offers a unique opportunity to intervene before life-threatening complications arise during or after pregnancy. demonstrates that identifying these risks early can better inform obstetric cardiovascular care, highlighting the need for AI tools that are tailored to specific clinical contexts rather than being applied as one-size-fits-all solutions. To evaluate the feasibility of these technologies, the research centers on several primary questions: To what extent do deep learning models improve the accuracy of early cardiovascular disease detection compared to traditional clinical methods in the United States? How do existing regulatory frameworks address the ethical risks of algorithmic bias and data privacy? Finally, what policy interventions are necessary to ensure that AI-driven diagnostics are deployed equitably across diverse demographic groups? The central hypothesis of this study is that while AI significantly enhances diagnostic precision, its clinical utility is maximized only when integrated into a governance framework that prioritizes algorithmic transparency and demographic equity. The primary aim of this research is to evaluate the efficacy and ethical governance of artificial intelligence-driven diagnostic tools for cardiovascular disease within the United States clinical environment. To achieve this, the study pursues four specific objectives:

1. Analyze the current state of AI-driven cardiovascular diagnostics to identify technological and clinical trends.

2. Evaluate the performance of deep learning models in early disease detection, specifically focusing on their predictive accuracy and time-to-event outcomes.

3. Examine the regulatory framework and ethical challenges of AI in US healthcare, with an emphasis on addressing algorithmic bias.

4. Propose improvements for equitable AI deployment that align technical capabilities with public health goals. The object of this study is Artificial Intelligence in cardiovascular disease management. The subject is the specific frameworks for early detection and the regulatory governance governing these technologies within the United States. By distinguishing between the technological medium (the AI) and the structural application (the governance and detection frameworks), this research provides a nuanced analysis of how innovation interacts with policy. The scope of this work is delimited to the United States clinical environment between 2020 and 2026, focusing on deep learning applications in early CVD detection. While AI has applications in robotic surgery and post-operative care, these areas fall outside the current inquiry. The study focuses specifically on diagnostic and predictive tools used in primary care and cardiology settings. provides a systematic review of AI models for time-to-event outcomes, which serves as a critical technical boundary for evaluating risk prediction models in this research. Non-clinical wellness apps and consumer-grade wearables are excluded unless their data is integrated into a formal clinical diagnostic pathway. The theoretical significance of this research lies in its contribution to the emerging field of digital health ethics and algorithmic governance. It challenges the assumption that technical accuracy is the sole metric of success for medical AI, arguing instead for a multi-dimensional evaluation of "clinical trust." By synthesizing findings from and, this study builds a theoretical bridge between data science and health policy. On a practical level, the findings provide a roadmap for healthcare administrators and policymakers to implement AI tools that are both effective and socially responsible. The proposed improvements for equitable deployment offer actionable strategies to mitigate bias, ensuring that advancements in AI-driven imaging and screening benefit the entire US population. The methodology employed is a qualitative and quantitative synthesis of current literature, clinical trial data, and policy documents. Data collection involves a systematic review of peer-reviewed journals, FDA regulatory filings, and health policy briefs published between 2024 and 2026. This approach allows for a rigorous comparison of different deep learning architectures—such as Convolutional Neural Networks for imaging and Recurrent Neural Networks for longitudinal EHR data—against established clinical benchmarks. The analysis utilizes a comparative framework to evaluate how different governance models impact the speed and safety of AI adoption in various US hospital systems. The structure of this diploma is organized to move from technical analysis to policy recommendation. The first chapter provides an exhaustive review of the current AI landscape in US cardiology, detailing the transition from traditional statistics to machine learning. The second chapter focuses on the performance metrics of deep learning models, utilizing evidence from recent systematic reviews to assess their predictive power. The third chapter shifts to the ethical and regulatory dimensions, analyzing the specific mechanisms of bias and the current limitations of US health policy. Finally, the fourth chapter synthesizes these insights to propose a new framework for the equitable and transparent deployment of AI in cardiovascular care, followed by a summary of findings and suggestions for future research.